IMvigor011 Trial: ctDNA Helps Determine Which Bladder Cancer Patients Will Benefit From Adjuvant Immunotherapy

Muscle-invasive bladder cancer (MIBC) is a challenging disease with a high rate of relapse despite aggressive neoadjuvant therapy before a cystectomy. Currently, the National Comprehensive Cancer Network (NCCN) guidelines identify certain high-risk patients who may benefit from adjuvant immunotherapy. However, this may lead to over-treatment.

The IMvigor011 Trial sought to identify high-risk patients post-cystectomy who may benefit from adjuvant atezolizumab by using circulating tumor cell DNA (ctDNA).

“They had patients who underwent surgery and then if they had an elevated [ctDNA] afterwards, they were randomized to getting atezolizumab or not getting it, and the survival was much better in the ctDNA positive patients who got atezolizumab,” Dr. Piyush Agarwal, a urologic oncologist at the University of Chicago, tells SurvivorNet Connect.

Patient Selection & Trial Design

The trial enrolled patients with high-risk urothelial carcinoma after radical cystectomy (with or without prior neoadjuvant chemotherapy) who had no radiographic evidence of metastatic disease. All patients underwent serial tumor-informed ctDNA testing using a personalized assay. Notably, the patients were not randomized immediately after surgery.

Instead, they were observed with serial blood draws, and only those who converted to ctDNA-positive status were randomized in a 2:1 fashion to atezolizumab versus placebo for up to one year.

Patients who remained persistently ctDNA-negative received no adjuvant systemic therapy. The primary endpoint was disease-free survival, with overall survival and toxicity as key secondary endpoints.

Study Results 

• ctDNA-Positive Randomized Cohort (atezo vs placebo): DFS improvement: HR ~0.64 (p < 0.005), median DFS ~9.9 months (atezo) vs ~4.8 months (placebo). OS benefit: HR ~0.59 (p ∼ 0.01), median OS ~32.8 months vs ~21.1 months, 12-month DFS and OS rates both favored atezolizumab.
• ctDNA-Negative Surveillance Group: Very favorable outcomes without therapy: ~95% DFS at 1 year and ~88% at 2 years, suggests low relapse risk in patients without detectable MRD.

Implications For Future Bladder Cancer Management

This design is clinically elegant. It enriches the randomized population for patients at the highest risk of relapse — those with molecular evidence of residual disease — while simultaneously creating a prospective observational cohort of ctDNA-negative patients.

From a practical standpoint, it answers two questions at once: does immunotherapy help molecularly positive patients, and can molecularly negative patients safely avoid treatment?

The results were practice-informing. Among ctDNA-positive patients, adjuvant atezolizumab significantly improved disease-free survival compared with placebo, with a hazard ratio of approximately 0.6.

Overall survival (OS) also favored atezolizumab, an important distinction given how difficult it has been to demonstrate an OS benefit in the adjuvant bladder cancer space.

Median disease-free survival (DFS) was meaningfully prolonged, and early separation of curves suggested that treating at molecular relapse delays or prevents radiographic recurrence.

Equally striking were the outcomes in the ctDNA-negative cohort. These patients had excellent disease-free survival without any systemic therapy, reinforcing the prognostic strength of ctDNA negativity.

For a clinician, this is arguably as important as the positive treatment result: we may finally have a tool to avoid over-treatment in a population historically subjected to empiric adjuvant therapy strategies with marginal benefit.

From a mechanistic standpoint, the study supports the idea that immune checkpoint inhibition is more effective when tumor burden is low but present, precisely the MRD state. It also underscores that radiographic “no evidence of disease” does not equate to biologic cure. ctDNA appears to detect recurrence months before imaging, potentially creating a therapeutic window.

“Essentially ctDNA can provide guidance as to which patients should receive immunotherapy after surgery, at least when it comes to atezolizumab,” Dr. Agarwal says. “Now, of course, that hasn’t been tested in Keytruda (pembrolizumab), so right now if patients get that immune checkpoint, all the patients are getting that. But what’s happening is that we, as providers, are extrapolating that data. And so a lot of us are checking ctDNA on our patients after surgery, and if it’s elevated, that’s when we are usually advising some form of immune checkpoint therapy.”

Limitations

Follow-up remains relatively early for definitive conclusions on survival in MIBC, and longer-term durability data will matter. Implementation outside of a clinical trial requires reliable access to tumor-informed ctDNA assays, rapid turnaround times, and payer coverage. Cost-effectiveness analyses will be critical, particularly since serial ctDNA surveillance plus immunotherapy is resource-intensive.

Additionally, while ctDNA negativity is highly prognostic, it is not infallible. Rare late recurrences may still occur, and the optimal duration and frequency of testing are not yet standardized.

Another practical consideration is how this integrates with other adjuvant data. Trials such as CheckMate 274 established the role of adjuvant nivolumab in an unselected high-risk population. IMvigor011 challenges the empiric approach by suggesting that a biomarker-directed strategy may be superior in risk stratification.

It raises a real-world clinical question: should we treat all high-risk patients up front, or surveil with ctDNA and intervene selectively? Despite these concerns, Dr. Agarwal is confident that “the IMvigor study essentially confirms that that is a valid approach because you can still treat those patients and have really good outcomes.”